News

Read our latest news.

  • July 12, 2022

BostonGene Announces New Master Agreement with Leading Cancer Center in New York City

More
  • June 3, 2022

BostonGene to Present at the 2022 American Society of Clinical Oncology Annual Meeting

More
  • May 10, 2022

BostonGene Announces Integration With NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

More
  • April 7, 2022

BostonGene Announces Acceptance of Six Abstracts to be Presented at the American Association for Cancer Research Annual Meeting 2022

More
  • April 6, 2022

BostonGene Announces $150 Million Series B Funding at a Multi-Billion Dollar Valuation, Propelling the Company to Unicorn Status

More
  • March 15, 2022

BostonGene and Thomas Jefferson University Announce Publication in Clinical Cancer Research Predicting Immunotherapy Response for Patients with Head and Neck Cancer

More
  • February 22, 2022

BostonGene Earns Recognition from Cancer Cell for its State-of-the-Art Technology in Cancer Research and Oncology

More
  • February 8, 2022

BostonGene Expands Testing Capabilities to Predict Patient Response to Immunotherapy

More
  • January 11, 2022

BostonGene and WellDyne Announce Strategic Partnership to Predict Immunotherapy Response and Reduce Overall Cost of Care in Cancer

More